Although HDAC inhibitors have shown success in preventing graft versus host disease (GVHD) [61] and treating patients with T-cell lymphoma [62] and multiple myeloma [63, 64]; to date, no study has shown significant benefit in patients with solid tumors [65, 66]. This evidence concerns the gene HDAC9 and graft versus host disease.